Catalent Sells New Jersey Facility and HQ to Ardena, Expanding Belgian CDMO’s US Footprint

Sale Agreement:
Catalent has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, New Jersey, to Belgian CDMO Ardena.

Facility Details:
The Somerset facility employs approximately 200 skilled scientists and technicians and is a Center of Excellence for advanced delivery of oral dosage forms.

Acquisition Impact:
The acquisition will significantly enhance Ardena’s capabilities in downstream late-stage and small-scale commercial manufacturing of oral drug products, supporting its strategy to become a leading global CDMO.

Transition Period:
Catalent’s corporate headquarters, currently housed at the Somerset site, will remain there during a transition period before shifting to a new location, which will be announced at a later date.

Closing Date:
The transaction is expected to close in early 2025, subject to regulatory approvals and other customary closing conditions.

Strategic Expansion:
This acquisition marks a significant milestone in Ardena’s international growth strategy, expanding its bioanalytical services in the US and aligning with its expertise in developing innovative nanomedicine drug delivery systems.